EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische Studie

Dosimetry and Toxicity Comparison of Three-Dimensional Conformal Radiation Therapy and Intensity Modulated Radiation Therapy in Locally Advanced Lung Cancer Across a Large Statewide Quality Collaborative

Steven G Allen, Caitlin A Schonewolf, Matthew J Schipper, Huiying Maggie Yin, Peter A Paximadis, Larry L Kestin, Michael Dominello, Melissa Wilson, Martha M Matuszak, James A Hayman, Shruti Jolly

International Journal of Radiation Oncology*Biology*Physics · 2025

DOI: 10.1016/j.ijrobp.2025.03.007 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Steven G Allen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. Hauptthemen laut MEDLINE: Radiotherapy, Intensity-Modulated, Lung Neoplasms, Radiotherapy, Conformal, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Varian Medical Systems, AstraZeneca, Blue Cross Blue Shield of Michigan Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Use of intensity modulated radiation therapy (IMRT) versus three-dimensional conformal external beam radiation therapy (3D-CRT) for definitive chemoradiation therapy (CRT) in locally advanced non-small cell lung cancer (LA-NSCLC) has been associated with decreased late pneumonitis, decreased high dose to the heart (itself associated with improved overall survival), and improved patient quality of life. In a statewide radiation oncology quality consortium, we sought to evaluate the impact of IMRT versus 3D-CRT treatment technique on dosimetry and toxicity. METHODS AND MATERIALS: From 2012 to 2022, 1746 LA-NSCLC patients meeting inclusion criteria underwent definitive RT (90% CRT) with either 3D-CRT (n = 313) or IMRT (n = 1433) and were enrolled in the Michigan Radiation Oncology Quality Consortium (MROQC) prospective, multicenter statewide initiative. Physician reported toxicity and patient-reported outcomes (PROs) were collected during treatment through 6 months after RT and compared by treatment technique. Inverse probability of treatment weighting (IPTW) was used to account for differences in prognostic factors between IMRT and 3D-CRT patients. RESULTS: Compared with 3D-CRT patients, IMRT patients had significantly larger PTVs (median 386 cc vs 292 cc; P < .0001) and were more likely to have Stage IIIB disease (34.3% vs 23.0%; P < .0001). After adjustment using IPTW, treatment with IMRT compared with 3D-CRT reduced high dose to the lung (mean V30 Gy 17.9% vs 19.2%; P = .027) and heart (proportion with V40 Gy ≥ 20% 6.4% vs 15.3%; P < .0001). In logistic regression models using IPTW, through 6 months of early follow-up, there were no significant differences between 3D-CRT and IMRT in rates of grade 2+ acute esophagitis (odds ratio [OR] = 1.02; 95% CI, 0.73,1.42; P = .91) and grade 2+ early pneumonitis (OR = 1.62; 95% CI, 0.89, 2.96; P = .11) or in likelihood of a clinically significant decline in PROs. CONCLUSIONS: With late follow-up ongoing, this study supports the continued preferential use of IMRT over 3D-CRT for LA-NSCLC treatment due to improvements in heart and lung doses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Radiotherapy, Intensity-ModulatedLung NeoplasmsRadiotherapy, ConformalCarcinoma, Non-Small-Cell LungHumansMaleFemaleMiddle AgedAgedRadiotherapy DosageRadiation PneumonitisOrgans at RiskHeartPatient Reported Outcome MeasuresMichiganProspective StudiesAged, 80 and overQuality of Life

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
  • Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Department of Biostatistics, University of Michigan, Ann Arbor, Michigan.
  • Corewell Health South, St. Joseph, Michigan.
  • Michigan Health Professionals, Farmington Hills, Michigan.
  • Karmanos Cancer Institute, Detroit, Michigan.
  • Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. Electronic address: shrutij@med.umich.edu.

Förderung

  • Varian Medical Systems
  • AstraZeneca
  • Blue Cross Blue Shield of Michigan Foundation

Zitieren

APA

Allen, S. G., Schonewolf, C. A., Schipper, M. J., Yin, H. M., Paximadis, P. A., Kestin, L. L., Dominello, M., Wilson, M., Matuszak, M. M., Hayman, J. A., & Jolly, S. (2025). Dosimetry and Toxicity Comparison of Three-Dimensional Conformal Radiation Therapy and Intensity Modulated Radiation Therapy in Locally Advanced Lung Cancer Across a Large Statewide Quality Collaborative. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.03.007

Vancouver

Allen SG, Schonewolf CA, Schipper MJ, Yin HM, Paximadis PA, Kestin LL, et al. Dosimetry and Toxicity Comparison of Three-Dimensional Conformal Radiation Therapy and Intensity Modulated Radiation Therapy in Locally Advanced Lung Cancer Across a Large Statewide Quality Collaborative. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2025.03.007

BibTeX
@article{Allen2025,
  author = {Allen, Steven G and Schonewolf, Caitlin A and Schipper, Matthew J and Yin, Huiying Maggie and Paximadis, Peter A and Kestin, Larry L and Dominello, Michael and Wilson, Melissa and Matuszak, Martha M and Hayman, James A and Jolly, Shruti},
  title = {Dosimetry and Toxicity Comparison of Three-Dimensional Conformal Radiation Therapy and Intensity Modulated Radiation Therapy in Locally Advanced Lung Cancer Across a Large Statewide Quality Collaborative},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2025},
  doi = {10.1016/j.ijrobp.2025.03.007}
}
Kostenlos starten →